Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New registry tracks Real-World impact of liver drug for rare childhood disease

NCT ID NCT07185919

First seen Sep 30, 2025 · Last updated May 21, 2026 · Updated 29 times

Summary

This study follows up to 10 people with progressive familial intrahepatic cholestasis (PFIC) who are taking odevixibat (Bylvay) as part of their regular care. Researchers will collect information on how well the drug controls symptoms like itching and jaundice, and monitor for any side effects over time. The goal is to understand the medicine's long-term safety and effectiveness in everyday use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Pusan National University Yangsan Hospital

    ACTIVE_NOT_RECRUITING

    Gyeongsang, South Korea

  • Seoul National University Hospital

    NOT_YET_RECRUITING

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    RECRUITING

    Seoul, South Korea

Conditions

Explore the condition pages connected to this study.